- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 05.02. | Bayer details anticipated stroke prevention data for new blood-thinner | ||
| 05.02. | Generate, an AI-driven Flagship startup, pitches an IPO | ||
| 05.02. | Express Scripts reaches 'landmark' settlement with FTC in insulin suit | ||
| 05.02. | Eikon Therapeutics nets a $381M IPO amid burst of biotech offerings | ||
| 04.02. | Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions | ||
| 04.02. | Novo shares tumble by double digits on grim sales outlook | ||
| 04.02. | Lilly soars again as fast-selling weight loss drugs top Wall Street projections | ||
| 04.02. | Earnings roundup: Amgen vs. FDA, Pfizer's defense and Merck's $70B-in-sales plan | ||
| 03.02. | Pfizer dips on new data for obesity drug acquired in $10B deal | ||
| 03.02. | FDA launches 'PreCheck' program; AstraZeneca, Acadia drugs set back | ||
| 02.02. | Novo combination obesity shot meets goal in diabetes trial | ||
| 02.02. | Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials | ||
| 02.02. | GSK walks away from pioneering Wave RNA editing drug | ||
| 02.02. | Building a robust in-process testing plan for cell therapy manufacturing success | ||
| 30.01. | Amgen gives up on its once-prized eczema drug | ||
| 30.01. | AstraZeneca leans into obesity, striking wide-ranging alliance with China's CSPC | ||
| 30.01. | Politicization runs deeper than ever at FDA, risking long-term impacts | ||
| 29.01. | The biopharma industry outlook on 2026: Optimism and tension | ||
| 29.01. | Sanofi expects vaccine sales growth to dip amid 'challenging environment' | ||
| 29.01. | AstraZeneca strengthens China ties with planned $15B investment | ||
| 29.01. | Tenpoint wins FDA nod for combination presbyopia eye drop | ||
| 28.01. | Lilly bets on Seamless, delving further into genetic medicine for hearing loss | ||
| 28.01. | Drugs for cancer, arthritis and HIV on Medicare's list for 2028 price cuts | ||
| 28.01. | Halozyme buys a biotech startup; Cytokinetics launches heart drug | ||
| 28.01. | Regenxbio gene therapy trials suspended by FDA over safety worries |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.